202484-91-1
202484-91-1
Chemical Structure
Prexigebersen
Synonym(s): BP1001
- CAS No.: 202484-91-1
- Formula:N/A
- Molecular Weight:5520.57
SMILES: [Prexigebersen]
Biological Activity: Prexigebersen (BP1001) is an antisense oligonucleotide targeting Bcl-2 and Grb2. Prexigebersen exhibits antileukemic activity in cell models. Prexigebersen induces apoptosis (apoptosis), cell cycle arrest and ROS production in leukemia cells. Prexigebersen inhibits Grb2 expression, thereby suppressing tumor growth and survival. Prexigebersen can be used in studies related to acute myeloid leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Prexigebersen | Prexigebersen (BP1001) is an antisense oligonucleotide targeting Bcl-2 and Grb2. Prexigebersen exhibits antileukemic activity in cell models. Prexigebersen induces apoptosis (apoptosis), cell cycle arrest and ROS production in leukemia cells. Prexigebersen inhibits Grb2 expression, thereby suppressing tumor growth and survival. Prexigebersen can be used in studies related to acute myeloid leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yuan KN, et al. A Photoelectrocatalytic Platform for Sequence-Unrestricted Modification of Oligonucleotide Backbones. Angew Chem Int Ed Engl. 2026;65(6):e24814. [Content Brief]
-
[2]. Maro Ohanian, et al. Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients
with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML). Volume 138, Supplement 1, 23 November 2021, Page 1281.
Keywords
